Genuity Capital Markets
http://www.genuitycm.com/Genuity Capital Markets is a financial services firm providing investment banking, institutional sales and trading, and equity research to its corporate clients. The firm uses a simple Buy, Hold and Sell rating system in its research analysis.
View Older Stories View More Recent Stories
-
Canaccord Genuity Maintains a 'Hold' on Smith Micro Software (SMSI); Q3/11 Earnings: Target Return to Profits in 3-5 Quarters
-
Canaccord Genuity Reiterates a 'Buy' on AMD (AMD); Cutting Costs While Refocusing R&D
-
Canaccord Genuity maintains a 'Hold' on NetSuite (N); Once Again, a Solid Quarter; We Will Wait for Break in Stock Price
-
Canaccord Genuity Reiterates a 'Buy' on Apple (AAPL); Checks Show Record iPhone Launch; Raising Estimates & PT
-
Canaccord Genuity Maintains a 'Hold' on Transocean (RIG); Waiting for Improved Operations
-
Canaccord Genuity Maintains a 'Buy' on Continental Resources (CLR); Q3/11: Successful Lower Three Forks Test tTough higher gas Weighting/Lower '12 CapEx
-
Canaccord Genuity Reiterates a 'Buy' on ENSCO International (ESV); Positive Earnings Momentum
-
Canaccord Lifts Target on Chesapeake Energy (CHK) from $48 to $49, Maintains Buy
-
Canaccord Genuity Reiterates a 'Buy' on Approach Resources (AREX); Wolfcamp Progress Confirms our Bullish Permian Stance
-
DragonWave Plans to Acquire Nokia Siemens Networks Microwave Transport Business
-
DragonWave Plans to Acquire Nokia Siemens Networks Microwave Transport Business
-
3P International Energy Corp. Announces Letter of Intent to Acquire A 30% Interest in Five License Areas in the Dnieper-Donetsk Basin of Eastern Ukraine Through Business Combination
-
3P International Energy Corp. Announces Letter of Intent to Acquire A 30% Interest in Five License Areas in the Dnieper-Donetsk Basin of Eastern Ukraine Through Business Combination
-
Canaccord Genuity Cuts Eldorado Gold Corp (EGO) to Hold, Maintains $21.50 Target
-
Canaccord Genuity Reiterates a 'Hold' on Edwards Lifesciences (EW); SAPIEN Approved as Expected
-
Canaccord Genuity Maintains a 'Buy' on Zalicus (ZLCS); Q3/11 Update: Synavive Ph 2 Enrollment on Track
-
Canaccord Genuity Reaffirms a 'Buy' on Teva Pharma (TEVA); Improved visibility, Reset EPS and Catalyst Ahead
-
Canaccord Genuity Reiterates a 'Buy' on Onyx Pharmaceuticals (ONXX); Nexavar Margins Improve, Big Catalysts Approach
-
Canaccord Genuity reiterates a 'Buy' on Gen-Probe (GPRO); Solid Q3 - Focus Shifts to Marketing HPV Assay in US
-
Canaccord Genuity Maintains a 'Buy' on DexCom (DXCM); Q3 Miss; Q4 Revenue Guidance Lowered, Resetting the Bar Appropriately
-
Canaccord Genuity Maintains a 'Buy' on Dendreon (DNDN); Provenge Sales Struggle
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Q3 Good but Product Approvals Nearing
-
Canaccord Genuity Maintains a 'Buy' on Orion Energy Systems (OESX); Anticipating a Strong Second Half
-
Canaccord Genuity Reiterates a 'Buy' on Sierra Wireless (SWIR); Solid Q3/11 Results; M2M Growth Thesis Intact but Mobile Computing Uncertainty
-
Canaccord Genuity Maintains a 'Buy' on Qualcomm (QCOM); Strong Results and Guidance; Analyst Day Next Catalyst
-
Canaccord Genuity Reiterates a 'Buy' on Pioneer Natural Resources (PXD); Q3/11: Wolfcamp Takes the Stage, Eagle Ford Progressing Nicely
-
Canaccord Genuity Reiterates a 'Buy' on REX Energy (REXX); Initial Utica Result Confirms Depth & Potency of Asset Base
-
Canaccord Genuity Maintains a 'Buy' on Forest Oil (FST); Q3/11: Improving Granite Wash, Outstanding Hogshooter Test
-
Vox Telecom Selects Sandvine and Core2Africa for Usage Management Solution
-
Vox Telecom Selects Sandvine and Core2Africa for Usage Management Solution
-
Canaccord Genuity Maintains a 'Buy' on Vical (VICL); Q3/11 Update: A7 Data Still Expected Q2/12
-
Canaccord Genuity Maintains a 'Buy' on Watson Pharmaceuticals (WPI); Post Q3 - Beat and Raise Story Still There, as are Catalysts
-
Canaccord Genuity Reiterates a 'Buy' on Solta Medical (SLTM); Q3/11 Strong: Systems, Tips and All Geographies Contribute
-
Canaccord Genuity reiterates a 'Buy' on Amicus Therapeutics (FOLD); Q3/11: Upcoming Q4 Catalysts
-
Canaccord Genuity Reiterates a 'Buy' on Zimmer Holdings (ZMH); Q3/11 Results Reflective of Broader Industry Trends
-
Canaccord Genuity Maintains a 'Hold' on TranS1 Inc (TSON); Q3/11 Results Disappoint; Active Surgeons and US Case Volumes Pull Back
-
Canaccord Genuity Maintains a 'Hold' on Thoratec (THOR); Q3 Raises Questions, but We Remain Bullish About L-T Market Growth
-
Canaccord Genuity Maintains a 'Hold' on Impax Laboratories (IPXL); Challenges Remain and Street EPS Need to Come Down
-
Canaccord Genuity Maintains a 'Hold' on Genomic Health (GHDX); Q3 EPS Beats on Better GM and Spending
-
Canaccord Genuity Removes Alphatec (ATEC) From Best Ideas List; Q3/11 US Strength Offsets EU Weakness
-
Canaccord Genuity Reiterates a 'Buy' on Pharmasset (VRUS); PH 3 Plans in Place
-
Canaccord Genuity Maintains a 'Hold' on Westport Innovations (WPRT); Quarter Performance Keeps the Pace
-
Canaccord Genuity Maintains a 'Buy' on Headwaters (HW); Transformation on Track
-
Canaccord Genuity Maintains a 'Buy' on Trimble Navigation (TRMB); Tekla and PeopleNet Acquisitions Result in Some Moving Parts, but Outlook Remains Strong
-
Canaccord Genuity Maintains a 'Hold' on Powerwave Technologies (PWAV); Q3/11 Earnings In-Line with Preannouncement: Visibility Limited
-
Canaccord Genuity Maintains a 'Hold' on Novatel (NVTL); Solid Q3/11, Lowering Estimates Due to More Gradual 2012 MiFi Sales Ramp
-
Canaccord Genuity Maintains a 'Buy' on DigitalGlobe (DGI); Revenue Shortfall in Commercial Should be Recouped
-
Canaccord Genuity Reiterates a 'Hold' on Cascade Microtech (CSCD); Reschedulings and Thailand Impact Results and Outlook
-
Canaccord Genuity Reiterates a 'Buy' on Atmel (ATML); Near-term Touch Adjustments, Secular Story Intact
-
Canaccord Genuity Maintains a 'Buy' on Comstock Resources (CRK); Q3/11: Shifting Capex Toward Higher Margin Eagle Ford
